Jun 2026 (Q2 FY26) — Aug 4, 2026
Exagen Q2 FY26 — Record Revenue, Volume, and Near Breakeven Adjusted EBITDA
Read the full callExagen (XGN) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Exagen earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 19.9 | +15.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -8.6 | +6.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -3.2 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$7.43 −3.76% · −$0.29
Performance −35.6% 1Y
1Y: $11.54 on 17 Oct 2025 → $7.43. High $11.96 (24 Oct 2025), low $2.65 (30 Mar 2026).
- Previous close
- $7.72
- 52-week range
- $2.65 – $11.96
- One year
- −36.60%
Overview
- Symbol
- XGN
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Exagen earnings calls (XGN)
Financials
What the filings say
Net profit, year on year: +28% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 13 | 14 | 15 | 17 | 17 | 17 | 17 | 20 |
| Expenses | 12 | -5 | 12 | 13 | 13 | 14 | 14 | 14 |
| Operating profit | -5 | -3 | -3 | -3 | -3 | -5 | -3 | -2 |
| Operating margin | −37.3% | −24.8% | −21.7% | −15.3% | −18.0% | −29.9% | −19.7% | −8.6% |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net profit | -5 | -4 | -4 | -4 | -7 | -5 | -4 | -3 |
| EPS ($ per share) | -0.28 | — | -0.20 | -0.21 | -0.31 | — | -0.17 | -0.13 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -153 | -165 | -181 | -208 | -256 | -279 | -294 | -314 |
| Total liabilities | 36 | 33 | 37 | 39 | 44 | 34 | 35 | 41 |
| Fixed assets | 2 | 1 | 2 | 5 | 8 | 5 | 5 | 7 |
| Total assets | 29 | 88 | 78 | 123 | 86 | 57 | 45 | 58 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -9 | -10 | -14 | -20 | -32 | -14 | -13 | -14 |
| Cash from investing | -0 | -0 | -0 | -2 | -4 | -1 | -1 | -1 |
| Cash from financing | 11 | 69 | -0 | 65 | -0 | -11 | -1 | 24 |
| Net cash flow | 2 | 59 | -15 | 42 | -37 | -26 | -14 | 10 |
| Capital expenditure | -0 | -0 | -0 | -2 | -4 | -1 | -1 | -1 |
| Free cash flow | -9 | -10 | -15 | -23 | -36 | -15 | -14 | -14 |
Insider filings
9 filings between Feb 24, 2026 and Sep 1, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$252.6K
4 sales by 2 insiders
Compensation
not trading decisions- 5
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Black Jeffrey G. | — | $154.5K | Sep 1, 2026 |
| ABALLI JOHN | — | $98.1K | Mar 3, 2026 |
Latest filings (19)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 1, 2026 | Black Jeffrey G. Chief Financial Officer | Award | 1,571 | $4.7K |
| Sep 1, 2026 | Black Jeffrey G. Chief Financial Officer | Sale | 20,614 | $148.8K |
| Mar 12, 2026 | Black Jeffrey G. Chief Financial Officer | Award | 75,000 | $237.0K |
| Mar 12, 2026 | ABALLI JOHN President and CEO | Award | 150,000 | $0 |
| Mar 3, 2026 | ABALLI JOHN President and CEO | Sale | 15,698 | $56.8K |
| Mar 3, 2026 | ABALLI JOHN President and CEO | Award | 2,535 | $7.8K |
| Feb 27, 2026 | Black Jeffrey G. Chief Financial Officer | Award | 1,511 | $4.6K |
| Feb 24, 2026 | ABALLI JOHN President and CEO | Sale | 11,430 | $41.3K |
| Feb 24, 2026 | Black Jeffrey G. Chief Financial Officer | Sale | 1,584 | $5.7K |
| Oct 16, 2025 | ABALLI JOHN President and CEO | Sale | 31,787 | $375.6K |
| Sep 2, 2025 | Black Jeffrey G. Chief Financial Officer | Sale | 20,466 | $200.4K |
| Mar 25, 2025 | NMSIC Co-Investment Fund, L.P. 10% owner | Sale | 350,000 | $1.16M |
| Feb 28, 2025 | ABALLI JOHN President and CEO | Award | 8,621 | $21.3K |
| Feb 21, 2025 | Black Jeffrey G. Chief Financial Officer | Award | 15,000 | $0 |
| Feb 21, 2025 | ABALLI JOHN President and CEO | Award | 112,500 | $0 |
| Nov 20, 2024 | NMSIC Co-Investment Fund, L.P. 10% owner | Sale | 200,000 | $660.0K |
| Nov 15, 2024 | Black Jeffrey G. Chief Financial Officer | Purchase | 22,298 | $66.4K |
| Nov 14, 2024 | ABALLI JOHN President and CEO | Purchase | 24,305 | $68.3K |
| Sep 1, 2024 | Black Jeffrey G. Chief Financial Officer | Award | 225,000 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for EXAGEN INC.
Free account. Everything above stays public.
Write why you follow EXAGEN INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading